Ascendis Pharma A/S, a biopharmaceutical company utilizing its proprietary TransCon technology to develop new treatments for rare diseases, announced comprehensive updates on August 6 regarding its clinical programs for achondroplasia and the commercial performance of its flagship growth hormone therapy in the United States. The cornerstone of this announcement was the release of topline Week 78 results from the COACH Phase 2 trial, which evaluates a novel combination therapy consisting of once-weekly TransCon CNP (navepegritide) and once-weekly TransCon hGH (lonapegsomatropin). The data suggests that this dual-action approach may provide unprecedented growth benefits for children living with achondroplasia, the most common form of disproportionate short stature.
The company also highlighted the rapid market penetration of YUVIWEL (the brand name for lonapegsomatropin) in the U.S. market. Jan Mikkelsen, President and Chief Executive Officer of Ascendis Pharma, emphasized that the uptake of YUVIWEL reflects a growing demand for differentiated therapies that prioritize patient outcomes and convenience through once-weekly dosing. The integration of these two therapies—TransCon CNP and TransCon hGH—represents a strategic shift in the management of achondroplasia, moving beyond single-pathway interventions toward a more holistic growth strategy.
The COACH Trial: Clinical Milestones and Efficacy Data
The COACH trial is a prospective, Phase 2, open-label study designed to assess the safety, tolerability, and efficacy of a combination regimen. The trial involves once-weekly TransCon CNP administered at 100 µg/kg/week alongside once-weekly TransCon hGH with a starting dose of 0.30 mg/kg/week. The participants include children with achondroplasia aged 2 to 11 years, divided into two distinct cohorts: those who were previously naïve to TransCon CNP treatment and those who had previously received TransCon CNP monotherapy in earlier clinical trials.
The Week 78 results demonstrated that the combination therapy continued to facilitate durable growth. Specifically, the mean annualized growth velocity (AGV) for participants either met or exceeded the 97th percentile of growth for children of average stature. This is a significant clinical benchmark, as it suggests the potential for children with achondroplasia to achieve growth rates comparable to their average-stature peers. Importantly, this growth was achieved without compromising the safety or tolerability of the treatment, with no new safety signals emerging during the 78-week period.
The trial population was carefully selected to be representative of the broader achondroplasia community. The naïve cohort (N=12) had a mean age of 5.26 years, while the previously treated cohort (N=9) had a mean age of 8.32 years. The latter group had already received TransCon CNP monotherapy for an average of 2.56 years, providing a longitudinal look at how these patients transition from monotherapy to combination therapy.
Background on Achondroplasia and Therapeutic Mechanisms
Achondroplasia is caused by a gain-of-function mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. This mutation leads to overactivity of the FGFR3 signaling pathway, which negatively regulates bone growth at the epiphyseal growth plate. The result is inhibited chondrocyte proliferation and differentiation, leading to the characteristic features of the condition: short limbs, a relatively long trunk, and a macrocephalic head.
Current therapeutic strategies focus on counteracting this overactive signaling. C-type natriuretic peptide (CNP) is a natural regulator of bone growth that antagonizes the FGFR3 pathway. However, natural CNP has an extremely short half-life in the body, lasting only minutes. Ascendis Pharma’s TransCon CNP (navepegritide) is designed to provide sustained release of active CNP, maintaining therapeutic levels with a once-weekly injection.
The addition of TransCon hGH (lonapegsomatropin) introduces a second mechanism of action. Growth hormone works through the IGF-1 pathway to promote longitudinal bone growth and metabolic health. By combining a CNP analog (which "releases the brakes" on bone growth set by the FGFR3 mutation) with a growth hormone (which "steps on the gas" for growth), Ascendis aims to optimize the skeletal development of children with achondroplasia more effectively than monotherapy alone.
Monotherapy Advancements and Skeletal Health Outcomes
While the combination therapy has garnered significant attention, Ascendis also provided updates on TransCon CNP monotherapy. In both completed and ongoing clinical trials, navepegritide has shown a consistent ability to improve height and other skeletal parameters. Data from the ApproaCH trial highlighted benefits that extend beyond linear growth, specifically focusing on lower-limb alignment and body proportionality.
Dr. Carlos Bacino, a Professor of Molecular and Human Genetics at Baylor College of Medicine and Texas Children’s Hospital, noted that TransCon CNP has demonstrated statistically significant improvements in height and lower-limb alignment compared to placebo. He emphasized that the once-weekly administration and low rate of injection site reactions—consistent with the incidence reported in the FDA-approved label for similar TransCon products—position it as a vital potential treatment option.
Lower-limb alignment is a critical secondary endpoint in achondroplasia research. Many individuals with the condition suffer from progressive bowing of the legs (genu varum), which can lead to chronic pain and the eventual need for invasive corrective surgeries. Evidence suggesting that pharmacologic intervention can improve alignment provides hope for reducing the long-term surgical burden on these patients.
Commercial Uptake and Patient Advocacy Perspectives
The U.S. launch of YUVIWEL has been met with a positive reception from both the medical community and patient families. The transition from daily growth hormone injections to a once-weekly format represents a major improvement in quality of life and treatment adherence. Jan Mikkelsen noted that the rapid uptake of the drug underscores the value of the TransCon platform in delivering highly differentiated profiles that meet unmet medical needs.
Patient advocacy groups have played a pivotal role in the development and reception of these therapies. Chandler Crews, Founder of The Chandler Project, highlighted the eagerness of parents to access emerging drug development programs. According to Crews, new treatment options like YUVIWEL and the potential approval of TransCon CNP provide hope for preventing the chronic complications of achondroplasia, such as mobility issues and chronic pain, which significantly impact quality of life.
Similarly, Mike Hughes, Chair of the Biotech Industry Liaison Committee for Little People of America (LPA), expressed encouragement regarding the continued research into outcomes beyond linear growth. Hughes stressed the importance of understanding how anatomical changes, such as improved limb alignment, translate into functional differences in mobility and a reduced need for future surgical interventions. The LPA emphasizes the need for clear, balanced evidence to help families make informed decisions that align with their personal values and goals.
Analytical Implications for the Pharmaceutical Landscape
The data released by Ascendis Pharma has significant implications for the competitive landscape of achondroplasia treatments. Currently, the market is primarily served by daily-injection therapies. The move toward once-weekly dosing—both for CNP and hGH—could shift the standard of care by improving patient compliance and reducing the psychological and physical burden of daily needle sticks.
Furthermore, the "combination therapy" approach is a relatively new frontier in rare skeletal diseases. If the 97th percentile growth velocity remains durable through later stages of clinical development, it may set a new benchmark for efficacy. Analysts suggest that the ability to offer a comprehensive "growth package" involving multiple pathways could give Ascendis a competitive edge over companies focused solely on the FGFR3 pathway.
From a regulatory perspective, the safety profile remains paramount. The fact that Week 78 results showed no new safety concerns is a positive indicator for future FDA and EMA filings. The low rate of injection site reactions is particularly notable, as this has historically been a challenge for peptide-based therapies.
Chronology of Development and Future Milestones
The development of the Ascendis achondroplasia pipeline has followed a rigorous clinical timeline:
- Early Development: Leveraging the TransCon platform to create navepegritide and lonapegsomatropin.
- ApproaCH Trial: Establishing the efficacy and safety of TransCon CNP monotherapy.
- ACcomplisH Trial: Further investigating the dose-response and long-term safety of CNP.
- COACH Trial Initiation: Launching the combination therapy study to explore synergistic effects.
- August 2024: Release of the Week 78 COACH data and update on U.S. YUVIWEL uptake.
Looking forward, the medical community awaits the final results of Phase 3 trials and the potential submission of New Drug Applications (NDAs) for the combination therapy. Continued monitoring of the COACH trial participants will be essential to determine if the growth velocity leads to a significant increase in final adult height and, more importantly, a reduction in the comorbid complications associated with the condition.
Conclusion
Ascendis Pharma’s recent updates represent a significant stride in the field of pediatric endocrinology and skeletal dysplasias. By demonstrating that a combination of TransCon CNP and TransCon hGH can drive growth at the 97th percentile of average-stature children while maintaining a favorable safety profile, the company is challenging existing treatment paradigms. The commercial success of YUVIWEL further validates the market’s appetite for once-weekly, patient-centric solutions. As the achondroplasia community moves toward more personalized and functional treatment goals, the data from the COACH and ApproaCH trials will serve as a foundational resource for families and clinicians navigating the evolving therapeutic landscape.
